Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines
Next Deadline
1083 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-08-14)
Due Date
August 14, 2028
Grace Period Ends
February 14, 2029
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 9, 2025 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Oct 9, 2024 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | Loading... |
| Oct 9, 2024 | 71AG | O | REGISTERED-SEC.71 ACCEPTED | Loading... |
| Oct 7, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Feb 9, 2024 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Oct 12, 2018 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Sep 21, 2018 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 21, 2018 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Sep 13, 2018 | GPAR | P | GRANT OF PROTECTION CREATED, TO BE SENT TO IB | Loading... |
| Aug 14, 2018 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 2, 2018 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| May 29, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 16, 2018 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| May 16, 2018 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| May 9, 2018 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Apr 26, 2018 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 25, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 13, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 8, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 7, 2018 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED | Loading... |
| Mar 1, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
[ Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; ] pharmaceutical preparations acting on the central nervous system [ ; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma ]
Classification
International Classes
005